GRP78 inhibitors (Amgen/Cancer Research Technology/Institute of Cancer Research)

N/A

Report date: 2025/01/26 16:08:36
NME

Base Information

Drug NameGRP78 inhibitors (Amgen/Cancer Research Technology/Institute of Cancer Research)
Drug Alias NameGRP78 inhibitors (Nuevolution/Cancer Research Technology/Institute of Cancer Research)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action78 kDa glucose-regulated protein inhibitors
Targets78 kDa glucose-regulated protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNuevolution AS
China Registration ClassN/A

Develop Information

Active CompaniesCancer Research TechnologyInstitute Of Cancer ResearchAmgen Inc
Inactive CompaniesNuevolution AS
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A